Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05602779
Other study ID # 22-08-7372
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 8, 2023
Est. completion date September 30, 2027

Study information

Verified date November 2023
Source University of Notre Dame
Contact Cheryl Lee, MS
Phone 574-631-5097
Email clee21@nd.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Suicidal thoughts, suicide attempts, and suicide are increasingly common in adolescence. Current face-to-face prevention approaches are of limited effectiveness, rely on extensive resources, and are at odds with adolescents' digital preferences. We will evaluate two unconventional but promising interventions delivered to 13- to 17-year-olds: transcutaneous vagus nerve stimulation to target emotion dysregulation, and a peer-support smartphone app to combat social isolation. If effective, these digitally-delivered interventions could reach far more adolescents at far lower cost than current approaches.


Description:

Over the past two decades, suicide rates have increased nearly 35% in the U.S., with upward trends in nearly all demographic groups. Further increases have occurred since the COVID-19 pandemic began. Despite ambitious goals for reducing suicides and significant federal and private investment, suicide rates continue to rise unabated. To date, the predominant approach to mitigating suicide risk in the U.S. is secondary prevention. Typically, these programs identify risk of recurrence among those who have already attempted suicide at least once. Although secondary prevention is crucial, the majority of deaths by suicide occur on first attempt. Thus, targeted primary prevention earlier in development is essential. Most current primary prevention programs are intensive, expensive, and delivered by highly trained mental health providers, who are in short supply. Traditional face-to-face therapy is also unavailable to many who live in underserved communities, and disliked by adolescents, who much prefer digital delivery on their devices. This high-risk, high-reward proposal addresses these limitations and needs. We use an experimental therapeutics approach to evaluate the independent and combined efficacies of two unconventional but scalable interventions: transcutaneous vagus nerve stimulation (tVNS) to target emotion dysregulation, and a peer-support smartphone app to combat social isolation. These low-cost interventions, which hold strong promise but have not been used before, can reach large numbers of adolescents, with much potential to reduce prospective suicide risk. We will enroll 212 adolescents, ages 13-17 years, who show elevations on at least two prominent risk factors for suicide (e.g., self-injury, maltreatment). Using a 2 × 2 design, adolescents will be assigned randomly to receive 30 days of treatment with: 1. tVNS to target emotion dysregulation, 2. a peer-support phone app to target social isolation, 3. tVNS + a peer-support phone app, or 4. enhanced treatment as usual with monitoring and access to resources. Intervention effects on mechanisms (emotion dysregulation, social isolation) proximal efficacy signals (e.g., physiological reactivity, self-harm) and target outcomes (suicidal ideation, suicidal behaviors) will be evaluated immediately post-intervention and at one-year follow-up. Treatment data will be monitored daily to fine-tune dosing of both interventions. This transformative and innovative proposal tests two novel, scalable preventive interventions designed to "meet adolescents where they are" by using digital technologies to address core mechanisms of suicide risk.


Recruitment information / eligibility

Status Recruiting
Enrollment 212
Est. completion date September 30, 2027
Est. primary completion date April 15, 2027
Accepts healthy volunteers No
Gender All
Age group 13 Years to 17 Years
Eligibility Inclusion Criteria: - Aged between 13 and 17 years, - Attend in person meetings in South Bend, IN or Rochester, NY. and, Two of the following which will be scored during the phone screen: - Engaged in non-suicidal self-harm 3 times in the past 6 months or more than 5 times in their life time, with one occurrence in the past year. - Show high scores on emotional dysregulation - Show high scores on social isolation - Show high scores on impulsivity - Show high scores on depression - Engage in alcohol or other substance use Exclusion Criteria: - Parent reported autism or schizophrenia - Implanted pacemaker or cardiac defibrillator, other implanted or metallic device - Pregnant or breast feeding - History of seizures or epilepsy - TMJ Disorder - Bells' Palsy - Impaired cranial nerve function - Facial Pain

Study Design


Related Conditions & MeSH terms


Intervention

Device:
tVns Program
Participants will use the Neuvana Xen device 30 minutes a day for 3 days. The device delivers stimulation through the left ear via an ear bud. Participants can use the device at any time of day.
Other:
Phone App Program
Participants will have access to a specially designed phone app in order to play a game designed for this study. Approximately half of the participants will be able to connect with a fellow participant who is matched as their peer for social support.
Combination Product:
tVNS and Phone App Program
Participants will have both the Neuvana Xen Device and the full version of our program's phone app. They will use the device and full app access for 30 days.
Other:
Enhanced Treatment as Usual
Participants will have access to our program's phone app so the can play the game and will be called weekly to complete risk assessments.

Locations

Country Name City State
United States University of Notre Dame South Bend Indiana

Sponsors (2)

Lead Sponsor Collaborator
University of Notre Dame University of Rochester

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline in Non-Suicidal Self Injury Behaviors at 30 Days Teens will be assessed at the baseline lab visit for emotion regulation and self-harm through questions on the Qualtrics survey (measures are Difficulties in Emotion Regulation Scale and the Youth Self Report). They will also complete a face-to-face interview with a trained staff member to assess their level of non-suicidal self-injury, suicide ideation, and suicide attempts. In addition, we will collect measures of psychophysiological reactivity (heart rate variability, cardiac pre-ejection period) to emotional challenge.
All participants will complete the same tasks at subsequent visits (post-treatment, on-year follow-up) and it is hoped that teens who have used the tVNS device for the 30-day intervention period will show improved responses. For the rate of change, we will use percentile ranking vis-a-vis national norms.
30 Days
Primary Improved Reports of Social Isolation and Loneliness Each participating teen will complete questions regarding feelings of loneliness and social isolation on the Qualtrics survey while in the lab at each visit. We are using the 8-item UCLA loneliness scale to measure this in each teen.
Some teens will be assigned to using the peer support phone app where they will be matched with another teen in this study. They will play a cooperative game with each other, and be able to text and share thoughts, feelings, etc. with each other. This app will hopefully improve teen's self-reported feelings of isolation and loneliness.
For the rate of change, we will use percentile ranking vis-a-vis national norms.
30 Days
Primary Improved Results from Participant's Typical Treatment Teens who are not placed in one of the active intervention groups will still be able to access our phone app which allows them to play a non-cooperative game on their own, and they are able to text with our team members during regular business hours. The added support will hopefully help their current treatment plan to improve their thoughts and behaviors in regard to suicidal ideation and self-harm.
For the rate of change, we will use percentile ranking vis-a-vis national norms.
30 Days
Secondary Adherence to tVNS and Phone App intervention from Baseline to 30 days. Using data from the Xen device and the phone app, we will be able to determine the number of occurances the device and app were accessed, as well as for how much time each was actively used. Participants will also report on acceptability, obtrusiveness, and favorability of both the device and the phone app. 30 Days
See also
  Status Clinical Trial Phase
Recruiting NCT05334381 - Navigating Mental Health Treatment for Black Youth N/A
Recruiting NCT04653337 - Neuroimaging Guided and Robot-assisted rTMS for Suicidal Ideation of Depression Phase 2
Terminated NCT04254809 - Evaluation of a Computerized Intervention for Learning to Re-Evaluate Suicidal Thoughts N/A
Recruiting NCT05848089 - Real-time Intervention for Suicide Risk Reduction N/A
Recruiting NCT06322199 - Differences Between Suicide Attempters and Suicide Ideators. Influence of the Brief Therapy Attempted Suicide Short Intervention Program (ASSIP) on Neuropsychological Correlates and Psychological Process Factors - Project 3
Completed NCT05280756 - Home-based tDCS for Prevention of Suicidal Ideation N/A
Not yet recruiting NCT06454136 - Pilot Trial of Mobile Technology for Adolescent Suicidality N/A
Completed NCT01944293 - Ketamine for Suicidality in Bipolar Depression Phase 1/Phase 2
Completed NCT02021344 - Mental Health First Aid for College Students N/A
Not yet recruiting NCT04686162 - Bae: A Smartphone Application for a Better Following Adolescents at Risk of Suicidal Behavior: Study of Acceptability and Preliminary Results of Efficacy N/A
Recruiting NCT05377177 - Cortical Inhibition as a Biomarker of Response in a Comparison of Bilateral Versus Unilateral Accelerated Theta Burst Stimulation for Suicidal Ideation in Treatment-Resistant Depression -COMBAT-SI N/A
Completed NCT05580757 - Pharmacists as Gate Keepers in Suicide Prevention: Needs of Pharmacists
Recruiting NCT05925322 - Brain Changes During Social Reward Psychotherapy for Mid- and Late-Life Suicidality N/A
Not yet recruiting NCT05427734 - Treating Drivers of Suicide Using Jaspr Health N/A
Recruiting NCT04112368 - Cyclical Neuroactive Steroid Changes, Arousal, and Proximal Suicide Risk: An Experimental Approach Phase 4
Completed NCT04026308 - Written vs Electronic Safety Planning Study N/A
Recruiting NCT05537376 - A Novel Peer-Delivered Recovery-Focused Suicide Prevention Intervention for Veterans With Serious Mental Illness N/A
Not yet recruiting NCT06311591 - Efficacy, Effectiveness, and Implementation of Jaspr Health in Emergency Department- Part B N/A
Recruiting NCT05894980 - How to Reduce Suicidal Thoughts and Impulsivity in Depression N/A
Not yet recruiting NCT05860257 - Transforming Adolescent Mental Health Through Accessible, Scalable, Technology-supported Small-group Instruction N/A